VIDEX
LOE ApproachingNDAORALFOR SOLUTIONPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 49m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX is an oral small-molecule antiviral approved in 1991 for treatment of HIV infection. The drug is formulated as a solution for oral administration and represents a legacy nucleoside reverse transcriptase inhibitor class. Mechanism of action involves inhibition of HIV reverse transcriptase, though modern antiretroviral regimens have largely superseded monotherapy approaches.
LOE Approaching
Declining
Significant competitive pressure (30/100) and approaching loss of exclusivity indicate a contracting commercial footprint with reduced headcount and focus on managed decline or exit strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
HIV Infections
Career Relevance
VIDEX offers minimal career growth or advancement opportunities given its LOE-approaching status, zero linked job openings, and competitive obsolescence in modern HIV treatment. Professionals assigned to this product should expect focus on margin protection, geographic retention in developing markets, and eventual transition to newer therapeutic franchises.
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.